A new trading day began on Friday, with Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) stock price down -5.43% from the previous day of trading, before settling in for the closing price of $3.87. AMLX’s price has ranged from $1.58 to $7.27 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 1970.62% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 54.70%. With a float of $63.79 million, this company’s outstanding shares have now reached $68.63 million.
In an organization with 123 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -43.25%, operating margin of -334.07%, and the pretax margin is -345.81%.
Amylyx Pharmaceuticals Inc (AMLX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Amylyx Pharmaceuticals Inc is 28.01%, while institutional ownership is 56.45%. The most recent insider transaction that took place on Mar 20 ’25, was worth 37,005. In this transaction Director of this company bought 10,000 shares at a rate of $3.70, taking the stock ownership to the 10,000 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Co-Chief Executive Officer sold 4,595 for $3.15, making the entire transaction worth $14,483. This insider now owns 3,196,648 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 54.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.21% during the next five years compared to -78.71% drop over the previous five years of trading.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Here are Amylyx Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.43, a number that is poised to hit -0.50 in the next quarter and is forecasted to reach -1.88 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.55 million. That was inferior than the volume of 0.83 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 51.42%. Additionally, its Average True Range was 0.29.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 22.70%, which indicates a significant decrease from 43.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.31% in the past 14 days, which was lower than the 78.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.54, while its 200-day Moving Average is $3.39. However, in the short run, Amylyx Pharmaceuticals Inc’s stock first resistance to watch stands at $3.82. Second resistance stands at $3.99. The third major resistance level sits at $4.12. If the price goes on to break the first support level at $3.52, it is likely to go to the next support level at $3.39. The third support level lies at $3.22 if the price breaches the second support level.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
With a market capitalization of 324.29 million, the company has a total of 88,602K Shares Outstanding. Currently, annual sales are 87,370 K while annual income is -301,740 K. The company’s previous quarter sales were 420 K while its latest quarter income was -72,700 K.
